AMTB three-lens brief
Evidence-based stock research on AMTB. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 95% of its 52-week range — near the top of the band.
- Trading at 95% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Ex-dividend date 2026-11-13.
AMTB closed at $30.30 (+0.23%) as of 2026-11-12. Market cap: $1.20B. P/E (trailing) 17.9. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.. Concerns: trading at 95% of its 52-week range — near the top of the band.. Last quarter: Revenue $108.80M, net income $25.72M.
Why three lenses on AMTB, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMTB across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/AMTB" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMTB brief"></iframe>